ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2263

Obesity Independently Associates with Worse Patient Reported Outcomes in Women with Systemic Lupus Erythematosus

Sarah L. Patterson1, Gabriela Schmajuk2, Kashif Jafri3, Katherine D. Wysham3 and Patricia P. Katz4, 1Division of Rheumatology, University of California, San Francisco, San Francisco, CA, 2San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA, 3University of California, San Francisco, San Francisco, CA, 4Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Disease Activity, functional status, obesity, patient outcomes and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Patient Outcomes, Preferences, and Attitudes Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Obesity has been shown to exacerbate systemic inflammation in the general population and contributes to worse disease-related outcomes in rheumatoid arthritis. The impact of excess adiposity in systemic lupus erythematosus (SLE) has not been established despite obesity being a common comorbidity in SLE. We aimed to determine whether excess adiposity in women with SLE independently associates with worse patient reported outcomes (PROs).

Methods: Participants in this sample, drawn from the Arthritis Body Composition and Disability (ABCD) study, were at least 18 years old, female, and carried a diagnosis of SLE verified by medical record review. Body mass index (BMI) was calculated as weight (kg) divided by height (m2), and fat mass index (FMI), a measure of total fat mass adjusted for height, was assessed using whole dual x-ray absorptiometry (DXA). Two established definitions for obesity were used: FMI >=13 kg/m2 and BMI >=30 kg/m2. Dependent variables included 4 validated PROs: disease activity via Systemic Lupus Activity Questionnaire (SLAQ), depressive symptoms via Center for Epidemiologic Studies Depression Scale (CES-D), pain via Short Form 36 Health Survey (SF-36) Pain Subscale, and fatigue via SF-36 Vitality Subscale. We used multivariable linear regression to evaluate the associations of obesity with PROs while controlling for potential confounders (age, race, education, income, smoking, disease duration, disease damage, and prednisone use). We then calculated adjusted means for each outcome based on the multivariable regression.

Results: The sample (n=148) was 65% white, 14% Asian, and 13% African American; mean age 48 (± 12.3) years; 17% with poverty-level income; 86% with education beyond high school; mean disease duration 16 (± 9) years; and 45% taking glucocorticoids. 32% and 30% of participants met criteria for obesity by the FMI and BMI definitions, respectively. In the multivariate regression model, obesity defined by FMI associated with worse scores on each PRO: greater disease activity, higher levels of depressive symptoms, more pain, and more fatigue (Table). The same relationship between obesity and each of the reported PROs was observed after repeating the analyses using the traditional BMI >=30 kg/m2 cut-off.

Conclusion: In a representative sample of women with SLE, obesity (by FMI and BMI) independently associated with worse patient reported outcomes, including disease activity, depressive symptoms, and symptoms of pain and fatigue. Obesity may represent a modifiable target for improving outcomes in this patient population.

Table. Adjusted Means for Patient Reported Outcomes by Obesity Status

                    Adjusted Meana (95% CI)

Patient Reported Outcomes

Obeseb

Not Obese

P-value

Disease Activity (SLAQ)

14.8 (12.7-16.9)

11.5 (10.1-12.9)

0.010

Depression (CES-D)

19.8 (16.1-23.4)

13.1 (10.6-15.6)

0.004

Pain (SF-36 Pain)c

38.7 (35.7-41.7)

44.2 (42.2-46.3)

0.004

Fatigue (SF-36 Vitality)c

39.6 (36.2-43.0)

45.2 (42.9-47.6)

0.010

a Adjusted means calculated based on multivariate linear regression adjusted for age, race, education, income, smoking, disease duration, disease damage (Brief Index of Lupus Damage score), and prednisone use.

b Obesity defined by fat mass index >= 13 kg/m2

c Higher scores reflect better status (less pain/fatigue)

SLAQ – Systemic Lupus Activity Questionnaire

CES-D – Center for Epidemiologic Studies Depression Scale

SF-36 – Short Form 36 Health Survey


Disclosure: S. L. Patterson, None; G. Schmajuk, None; K. Jafri, None; K. D. Wysham, None; P. P. Katz, None.

To cite this abstract in AMA style:

Patterson SL, Schmajuk G, Jafri K, Wysham KD, Katz PP. Obesity Independently Associates with Worse Patient Reported Outcomes in Women with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/obesity-independently-associates-with-worse-patient-reported-outcomes-in-women-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/obesity-independently-associates-with-worse-patient-reported-outcomes-in-women-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology